| Pharmaceutical Information |
| Drug Name |
Levomilnacipran |
| Drug ID |
BADD_D02466 |
| Description |
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor. Chemically, levomilnacipran is the 1S,2R-enantiomer of milnacipran. FDA approved on July 25, 2013. |
| Indications and Usage |
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD). |
| Marketing Status |
approved; investigational |
| ATC Code |
N06AX28 |
| DrugBank ID |
DB08918
|
| KEGG ID |
D10072
|
| MeSH ID |
D000078862
|
| PubChem ID |
6917779
|
| TTD Drug ID |
D02XOK
|
| NDC Product Code |
65162-960; 65162-411; 65162-437; 65162-455; 68554-0115 |
| UNII |
UGM0326TXX
|
| Synonyms |
Levomilnacipran | Fetzima | Levomilnacipran Hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C15H22N2O |
| CAS Registry Number |
96847-54-0 |
| SMILES |
CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
